Approval
FDA Approves Perioperative Imfinzi Regimen
The FDA approved neoadjuvant Imfinzi plus enfortumab vedotin-ejfv followed by adjuvant Imfinzi for adults with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy. In the phase III VOLGA trial, the regimen reduced the risk of an event by 49% and the risk of death by 42% versus cystectomy with or without approved adjuvant treatment. Grade 3 or 4 adverse events occurred in 64% of patients receiving the regimen versus 44% in the comparator arm; applications are also under review in the EU, Japan and other countries.
- Drugdurvalumab
- Drugenfortumab vedotin
- TargetProgrammed cell death protein 1 ligand 1
- TargetNectin cell adhesion molecule 4
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.